| Vol. 13.08 – 1 March, 2022 |
| |
|
|
| As BCL2 was an important determinant of survival of both myeloid progenitor and B cells, researchers investigated whether clinical and molecular abnormalities arose in the myeloid compartment during long-term continuous venetoclax treatment of chronic lymphocytic leukemia in 89 patients. [Blood] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors profiled 26,407 fetal liver cells at both the transcriptional and protein level including ~7,000 highly enriched and functional fetal liver HSCs to establish a detailed molecular signature of engraftment potential. [Nature Communications] |
|
|
|
| Researchers showed that pyruvate dehydrogenase kinase 1 (PDK1) acted as a targetable determinant of different metabolic states in AML. [Nature Communications] |
|
|
|
| Scientists provided novel insights into HSC regulation during regeneration by focusing on mitochondrial metabolism and ATP citrate lyase. [EMBO Journal] |
|
|
|
| Pharmacological inhibition of ULK1 resulted in stress-induced differentiation of leukemic stem cells (LSCs), rendering them sensitive to tyrosine kinase inhibitor treatment, uncovering a promising strategy for selective eradication of LSCs in chronic myeloid leukemia patients. [Autophagy] |
|
|
|
| By combining single cell analyses and P53 conformation-specific monoclonal antibodies, scientists studied pre-leukemic-HSCs/progenitor cells from primary human DNMT3A-mutated AML samples. [Haematologica] |
|
|
|
| Investigators demonstrated that MutT homolog 1 was a potential druggable target expressed by the majority of AML patients and the inv(16)/KITD816Y AML mouse model mimicking the genetics of AML patients exhibiting poor response to standard chemotherapy. [Molecular Cancer therapeutics] |
|
|
|
| Scientists investigated whether gilteritinib, a selective FLT3 inhibitor, could enhance graft-versus-leukemia effects against FLT3-internal tandem duplication mutant (FLT3-ITD) transfected Ba/F3 leukemia in mice. [Bone Marrow Transplantation] |
| |
|
|
| Reduced-intensity conditioning for HLA-haploidentical hematopoietic cell transplantation was augmented with same-donor memory-like natural killer (NK) cells on day seven and three weeks of N-803 to treat patients with relapsed/refractory AML in a clinical trial. [Science Translational Medicine] |
|
|
|
| In CARTITUDE-1, five percent of patients with multiple myeloma reported movement and neurocognitive treatment-emergent adverse events with ciltacabtagene autoleucel, a B cell maturation antigen-targeted chimeric antigen receptor (CAR) T cell therapy. [Blood Cancer Journal] |
| |
|
|
|
| The role of tyrosine kinase inhibitors as protective factors against SARS-CoV-2 infection in patients with CML should be confirmed by large-scale epidemiologic studies. [Current Oncology Reports] |
|
|
|
| The authors highlight various studies on autophagic pathways and describe the role of autophagy in cancer, specifically AML. [Clinical and Translational Oncology] |
|
|
|
|
| Intellia Therapeutics, Inc. announced that the first patient has been dosed with NTLA-5001, the company’s ex vivo CRISPR/Cas9 genome editing candidate for the treatment of AML. [Intellia Therapeutics, Inc.] |
|
|
|
| Legend Biotech Corporation announced that the US FDA has approved its first product, CARVYKTIâ„¢ for the treatment of adults with relapsed or refractory multiple myeloma. [Legend Biotech Corporation] |
|
|
|
|
| April 6 – 9, 2022 Heidelberg, Germany |
|
|
|
|
|
| The University of California, Davis – Davis, California, United States |
|
|
|
| BC Cancer Research Institute – Vancouver, British Columbia, Canada |
|
|
|
| TU Dresden – Dresden, Germany |
|
|
|
| George Mason University – Prince William, Virginia, United States |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
|